Cheniere Energy, Inc. (AMEX) stock gained 2.73% to $13.94. The company, on July 17 2012, announced the pricing of its previously announced offering of its common stock at a price per share of $14.05. The size of the offering has been upsized from 20 million shares to 28 million shares. The offering is expected to close and settle on July 20, 2012. The Company intends to use the net proceeds from the offering to repay the $204.6 million principal amount outstanding of the 2.25% convertible notes due August 1, 2012, for capital expenditures on the Creole Trail Pipeline and for general corporate purposes.
Get Free Trend Analysis on LNG
Triangle Petroleum Corporation (AMEX:TPLM) stock increased 4.11% to $5.82. The 52 week trading range for the company is $3.00 - $8.26. Canaccord Genuity reiterated a 'Buy' on Triangle Petroleum with a price target of $11.00 (from $9.00) on July 6, 2012.
Should Investors Buy TMLP at CMP, Get Free Report
Medgenics Inc (AMEX:MDGN) stock declined 11.91% to $13.46. On July 17, 2012, Medgenics, Inc. (nyse mkt:MDGN and AIM)(nyse mkt:MEDG), announces the launch of its Phase IIa clinical trial in Israel of EPODURE(TM) Biopumps to treat anemia in patients with end-stage renal disease ("ESRD" or "kidney failure") on dialysis, through the sustained delivery of erythropoietin ("EPO"). Following the Israeli Ministry of Health's recent approval of the trial, Medgenics has enrolled and begun to treat the first two dialysis patients ever to receive EPODURE Biopumps.
Can MDGN rebound After Today’s Fall Get Trend Analysis
Rentech, Inc. (AMEX:RTK) shares fell 3.26% to $2.08. The 52 week trading range for the company is $0.72 - $2.40. The company is slated to hold its 2012 second quarter conference call on Friday, August 10, 2012 at 12:00 p.m. PDT, during which time Rentech's senior management will review the Company's financial results for the period and provide an update on corporate developments.
Get Free Trend Analysis on RTK
Hemispherx BioPharma, Inc (AMEX:HEB) shares increased 0.32% to $0.405 after the company announced that it has submitted a new drug application to ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, under the ANMAT's Orphan Drug regulations.